Compare · CCEL vs MGRX
CCEL vs MGRX
Side-by-side comparison of Cryo-Cell International Inc. (CCEL) and Mangoceuticals Inc. (MGRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CCEL and MGRX operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- CCEL is the larger of the two at $39.1M, about 11.3x MGRX ($3.5M).
- MGRX has been more active in the news (5 items in the past 4 weeks vs 3 for CCEL).
- Company
- Cryo-Cell International Inc.
- Mangoceuticals Inc.
- Price
- -
- -
- Market cap
- $39.1M
- $3.5M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- AMEX
- NASDAQ
- IPO
- 2022
- 2023
- News (4w)
- 3
- 5
- Recent ratings
- 0
- 0
Cryo-Cell International Inc.
Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, kidney, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It stores approximately 500,000 cord blood and cord tissue stem cells worldwide. The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.
Latest CCEL
- SEC Form 8-K filed by Cryo-Cell International Inc.
- SEC Form 4 filed by Cryo-Cell International Inc.
- SEC Form 4 filed by Cryo-Cell International Inc.
- SEC Form DEF 14A filed by Cryo-Cell International Inc.
- SEC Form 10-Q filed by Cryo-Cell International Inc.
- Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2026 Financial Results
- SEC Form 8-K filed by Cryo-Cell International Inc.
- Chairman, Co-CEO Portnoy David acquired $799,995 worth of shares (600,191 units at $1.33) and disposed of $799,995 worth of shares (600,191 units at $1.33), decreasing direct ownership by 71% to 247,438 units (SEC Form 4)
- SEC Form 10-Q filed by Cryo-Cell International Inc.
- Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2026 Financial Results
Latest MGRX
- Mangoceuticals Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form 1-A filed by Mangoceuticals Inc.
- Mangoceuticals Partners with T7X to Become the First Nasdaq-Listed Company to Offer Tokenized Preferred Stock on the T7X Platform
- SEC Form PRE 14A filed by Mangoceuticals Inc.
- Mangoceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Shareholder Director Nominations, Other Events
- SEC Form 8-K filed by Mangoceuticals Inc.
- SEC Form 424B5 filed by Mangoceuticals Inc.
- Mangoceuticals Closes Registered Direct Offering Priced at 74% Premium to Recent Market Close
- SEC Form 4 filed by Mangoceuticals Inc.
- SEC Form 4 filed by Mangoceuticals Inc.